- Home
- ASC vs ESPR Comparison
ASC vs ESPR Comparison
Compare ASC & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASC
- ESPR
- Stock Information
- Founded
- ASC 2010
- ESPR 2008
- Country
- ASC Bermuda
- ESPR United States
- Employees
- ASC N/A
- ESPR N/A
- Industry
- ASC Marine Transportation
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- ASC Consumer Discretionary
- ESPR Health Care
- Exchange
- ASC Nasdaq
- ESPR Nasdaq
- Market Cap
- ASC 510.3M
- ESPR 534.3M
- IPO Year
- ASC 2013
- ESPR 2013
- Fundamental
- Price
- ASC $11.32
- ESPR $2.50
- Analyst Decision
- ASC Buy
- ESPR Buy
- Analyst Count
- ASC 3
- ESPR 6
- Target Price
- ASC $12.67
- ESPR $6.50
- AVG Volume (30 Days)
- ASC 493.4K
- ESPR 7.0M
- Earning Date
- ASC 11-05-2025
- ESPR 11-06-2025
- Dividend Yield
- ASC 8.30%
- ESPR N/A
- EPS Growth
- ASC N/A
- ESPR N/A
- EPS
- ASC 1.04
- ESPR N/A
- Revenue
- ASC $324,200,000.00
- ESPR $268,125,000.00
- Revenue This Year
- ASC N/A
- ESPR $13.05
- Revenue Next Year
- ASC $18.36
- ESPR N/A
- P/E Ratio
- ASC $11.27
- ESPR N/A
- Revenue Growth
- ASC N/A
- ESPR N/A
- 52 Week Low
- ASC $8.32
- ESPR $0.69
- 52 Week High
- ASC $18.72
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- ASC 40.52
- ESPR 47.71
- Support Level
- ASC $11.38
- ESPR $2.35
- Resistance Level
- ASC $12.13
- ESPR $3.41
- Average True Range (ATR)
- ASC 0.29
- ESPR 0.18
- MACD
- ASC -0.18
- ESPR -0.03
- Stochastic Oscillator
- ASC 9.17
- ESPR 9.79
About ASC Ardmore Shipping Corporation
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The Company operates its business in one operating segment, the transportation of refined petroleum products and chemicals.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.